vs

Side-by-side financial comparison of AMREP CORP. (AXR) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $11.0M, roughly 1.3× C4 Therapeutics, Inc.). AMREP CORP. runs the higher net margin — 21.6% vs -186.0%, a 207.6% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 93.8%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs -13.6%).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

AXR vs CCCC — Head-to-Head

Bigger by revenue
AXR
AXR
1.3× larger
AXR
$14.6M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+19.0% gap
CCCC
112.8%
93.8%
AXR
Higher net margin
AXR
AXR
207.6% more per $
AXR
21.6%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
-13.6%
AXR

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AXR
AXR
CCCC
CCCC
Revenue
$14.6M
$11.0M
Net Profit
$3.1M
$-20.5M
Gross Margin
Operating Margin
20.6%
-210.1%
Net Margin
21.6%
-186.0%
Revenue YoY
93.8%
112.8%
Net Profit YoY
338.9%
40.7%
EPS (diluted)
$0.58
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
CCCC
CCCC
Q1 26
$14.6M
Q4 25
$9.4M
$11.0M
Q3 25
$17.9M
$11.2M
Q2 25
$11.2M
$6.5M
Q1 25
$7.5M
$7.2M
Q4 24
$11.9M
$5.2M
Q3 24
$19.1M
$15.4M
Q2 24
$19.5M
$12.0M
Net Profit
AXR
AXR
CCCC
CCCC
Q1 26
$3.1M
Q4 25
$1.2M
$-20.5M
Q3 25
$4.7M
$-32.2M
Q2 25
$3.9M
$-26.0M
Q1 25
$717.0K
$-26.3M
Q4 24
$4.0M
$-34.6M
Q3 24
$4.1M
$-24.7M
Q2 24
$4.1M
$-17.7M
Operating Margin
AXR
AXR
CCCC
CCCC
Q1 26
20.6%
Q4 25
11.9%
-210.1%
Q3 25
34.4%
-306.4%
Q2 25
31.7%
-441.0%
Q1 25
5.7%
-402.9%
Q4 24
26.4%
-728.4%
Q3 24
26.1%
-183.9%
Q2 24
23.9%
-178.6%
Net Margin
AXR
AXR
CCCC
CCCC
Q1 26
21.6%
Q4 25
12.8%
-186.0%
Q3 25
26.3%
-286.4%
Q2 25
34.8%
-402.6%
Q1 25
9.5%
-363.7%
Q4 24
33.9%
-667.8%
Q3 24
21.3%
-160.6%
Q2 24
21.2%
-147.6%
EPS (diluted)
AXR
AXR
CCCC
CCCC
Q1 26
$0.58
Q4 25
$0.22
$-0.09
Q3 25
$0.87
$-0.44
Q2 25
$0.73
$-0.37
Q1 25
$0.13
$-0.37
Q4 24
$0.75
$-0.50
Q3 24
$0.76
$-0.35
Q2 24
$0.77
$-0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$50.0M
$74.6M
Total DebtLower is stronger
$21.0K
Stockholders' EquityBook value
$139.4M
$256.6M
Total Assets
$143.9M
$359.1M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
CCCC
CCCC
Q1 26
$50.0M
Q4 25
$44.6M
$74.6M
Q3 25
$48.9M
$58.8M
Q2 25
$39.5M
$78.2M
Q1 25
$36.9M
$51.3M
Q4 24
$40.1M
$55.5M
Q3 24
$40.4M
$59.6M
Q2 24
$29.7M
$73.1M
Total Debt
AXR
AXR
CCCC
CCCC
Q1 26
$21.0K
Q4 25
$23.0K
Q3 25
$25.0K
Q2 25
$26.0K
Q1 25
$29.0K
Q4 24
$32.0K
Q3 24
$34.0K
Q2 24
$35.0K
Stockholders' Equity
AXR
AXR
CCCC
CCCC
Q1 26
$139.4M
Q4 25
$136.0M
$256.6M
Q3 25
$134.7M
$154.4M
Q2 25
$130.0M
$174.1M
Q1 25
$126.0M
$195.1M
Q4 24
$125.1M
$216.0M
Q3 24
$122.2M
$242.7M
Q2 24
$118.0M
$247.1M
Total Assets
AXR
AXR
CCCC
CCCC
Q1 26
$143.9M
Q4 25
$140.1M
$359.1M
Q3 25
$140.7M
$265.5M
Q2 25
$133.8M
$296.5M
Q1 25
$128.9M
$319.5M
Q4 24
$129.1M
$349.6M
Q3 24
$127.0M
$376.1M
Q2 24
$122.8M
$381.1M
Debt / Equity
AXR
AXR
CCCC
CCCC
Q1 26
0.00×
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
CCCC
CCCC
Operating Cash FlowLast quarter
$5.4M
$-22.1M
Free Cash FlowOCF − Capex
$5.4M
FCF MarginFCF / Revenue
37.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
CCCC
CCCC
Q1 26
$5.4M
Q4 25
$-4.3M
$-22.1M
Q3 25
$9.5M
$-31.2M
Q2 25
$10.2M
$-12.1M
Q1 25
$-3.2M
$-33.3M
Q4 24
$-182.0K
$-17.9M
Q3 24
$10.7M
$-24.1M
Q2 24
$10.7M
$-5.0M
Free Cash Flow
AXR
AXR
CCCC
CCCC
Q1 26
$5.4M
Q4 25
$-4.3M
Q3 25
$9.5M
$-31.6M
Q2 25
$9.7M
Q1 25
$-3.3M
Q4 24
$-268.0K
$-17.9M
Q3 24
$10.7M
$-24.1M
Q2 24
$10.3M
$-5.2M
FCF Margin
AXR
AXR
CCCC
CCCC
Q1 26
37.0%
Q4 25
-45.9%
Q3 25
53.2%
-281.5%
Q2 25
86.4%
Q1 25
-43.4%
Q4 24
-2.3%
-346.5%
Q3 24
55.8%
-157.2%
Q2 24
52.5%
-43.1%
Capex Intensity
AXR
AXR
CCCC
CCCC
Q1 26
0.1%
Q4 25
0.6%
Q3 25
0.1%
3.7%
Q2 25
5.2%
Q1 25
0.3%
Q4 24
0.7%
0.1%
Q3 24
0.2%
0.1%
Q2 24
2.3%
1.6%
Cash Conversion
AXR
AXR
CCCC
CCCC
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons